Methods: From 570 patients consecutive diagnosed with FL in 2 institutions between 2001
and 2014, we selected 349 patients (median age, 58 years; F/M 188/161; grade 1 74/297 …

Follicular lymphoma (FL) is an indolent disease characterized by long survival but frequent
relapses. Before the introduction of rituximab, the clinical course of these patients showed a …

Introduction In their lifetime, patients with follicular lymphoma frequently require multiple
treatments, which have improved their survival over the past few decades. The expected …

Abstract Abstract 1580 Background and aims The clinical course of patients with follicular
lymphoma (FL) in the pre-rituximab era was described by Johnson et al in 1995. It was …

Rituximab was approved in France in 2004, following randomized trials that demonstrated
efficacy in newly diagnosed high tumour burden follicular lymphoma (FL). This retrospective …

8512 Background: In FL, rituximab as a single agent obtains a response rate of 50–70% with
an EFS of 1–3 years depending on the population studied. Some patients respond to this …

Purpose Although the life expectancy of patients with follicular lymphoma (FL) has
increased, little is known of their causes of death (CODs) in the rituximab era. Patients and …

Purpose First-line treatment for patients with newly diagnosed follicular lymphoma (FL) still
remains debated, even in the rituximab-based combination therapy era. Few studies have …

Introduction Results of randomized studies showed benefit of maintenance therapy with
monoclonal anti-CD20 antibody (rituximab) in terms of time to progression (PFS) and overall …

Methods: The training cohort consisted of 263 patients (median age, 59 years; F/M, 142/121)
consecutively diagnosed with FL grades 1, 2 or 3a in two centers between 2004 and 2014 …